ArticleJournal of substance use2025
Buprenorphine provider preferences to expanding harm reduction services in rural and suburban primary care settings: a short report.
Article in Journal of substance use, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Introduction: The opioid overdose crisis continues to worsen in suburban and rural regions. Expanding harm reduction approaches in primary care offers a patient-centered approach to reduce opioid overdoses. Methods: We conducted a semi-structured survey among 26 buprenorphine prescribers to assess acceptability of office-based harm reduction strategies for people who use opioids (PWUOs) and expanding partnerships with community stakeholders to ensure low-threshold access to buprenorphine. Results: Respondents were mostly very or somewhat supportive of providing HIV testing (96.2%), information on opioid overdose prevention (100%), safe syringe disposal (100%) and use (100%), and referrals to free HIV testing (100%), social services (100%), naloxone sales in community pharmacies (96.2%) and partnering with pharmacists to facilitate referrals for patients requesting buprenorphine treatment (84.6%). Suggested strategies for enhancing care for PWUOs included addressing insurance-related barriers (e.g., prior authorization requirements, insufficient reimbursements), lifting of limits on patients prescribed buprenorphine, allowing for safe-injection sites, lifting urine drug testing requirements, integrating social services and mental health providers within primary care, and expanding the use of telebuprenorphine services. Conclusion: Findings from this study suggest strong buprenorphine provider support for adopting harm reduction strategies in primary care and collaborating with community pharmacists to facilitate referrals for PWUOs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.